Jacobs Levy Equity Management Inc. Buys 295,864 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Jacobs Levy Equity Management Inc. lifted its stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 163.4% in the third quarter, according to its most recent filing with the SEC. The fund owned 476,949 shares of the biotechnology company’s stock after acquiring an additional 295,864 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in Aldeyra Therapeutics were worth $2,571,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Perceptive Advisors LLC lifted its holdings in shares of Aldeyra Therapeutics by 7.9% during the 2nd quarter. Perceptive Advisors LLC now owns 9,275,851 shares of the biotechnology company’s stock worth $30,703,000 after acquiring an additional 682,265 shares during the last quarter. Federated Hermes Inc. bought a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth $1,758,000. PFG Investments LLC bought a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth $1,312,000. International Assets Investment Management LLC lifted its stake in Aldeyra Therapeutics by 397.0% in the third quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company’s stock worth $15,480,000 after purchasing an additional 229,487 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Aldeyra Therapeutics by 21.7% in the second quarter. Bank of New York Mellon Corp now owns 195,722 shares of the biotechnology company’s stock worth $648,000 after purchasing an additional 34,885 shares during the last quarter. 59.71% of the stock is owned by institutional investors.

Aldeyra Therapeutics Price Performance

Aldeyra Therapeutics stock opened at $5.22 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.80 and a quick ratio of 6.80. The firm has a fifty day simple moving average of $5.17 and a two-hundred day simple moving average of $4.69. Aldeyra Therapeutics, Inc has a twelve month low of $2.71 and a twelve month high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, hitting the consensus estimate of ($0.25). On average, research analysts predict that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.